Interestingly, NADPH oxidase NOX4-synthesized ROS inactivate phosphotyrosine phosphatase PP1α, thereby activating PI3K-AKT signaling and further strengthening CML cell drug resistance and cancer cell survival (252). The gene discussed is AKT1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.